Drug class in one race
SUR1 (short-acting) drugs for Type 2 Diabetes
3 tracked SUR1 (short-acting) drugs in the Type 2 Diabetes race. The class explanation lives on the SUR1 (short-acting) page; the full indication pipeline across every mechanism is on the Type 2 Diabetes page.
2 approved / phase 41 Phase 3
Head-to-head evidence: Mitiglinide vs Nateglinide · Mitiglinide vs repaglinide · Nateglinide vs repaglinide